Xcene Research

Executive Summary

Xcene Research is a Nigerian clinical research organization (CRO) founded in 2012, specializing in infectious disease and oncology trials across Africa. With a team of 50–200 employees, the company leverages its deep understanding of local diseases, patient populations, and regulatory landscapes to accelerate drug development. As Africa faces a rising burden of infectious diseases like tuberculosis, malaria, and HIV, as well as increasing cancer rates, Xcene Research positions itself as a critical partner for global pharmaceutical and biotech firms seeking to conduct trials on the continent. The company’s platform-stage status suggests it is building scalable infrastructure for multisite trials, electronic data capture, and community engagement, which could lower costs and improve patient retention. Despite limited public information, Xcene Research appears to be capitalizing on the growing trend of clinical trial decentralization and Africa’s emergence as a strategic hub for diverse patient recruitment. Its ability to navigate regulatory complexities and ethical considerations gives it a competitive edge in the region.

Upcoming Catalysts (preview)

• Q3 2026Announcement of major pharma partnership for infectious disease trial50% success
• Q4 2026Expansion into East African market with new trial site70% success
• Q1 2027Publication of Phase II oncology trial results in collaboration with international partner40% success